Vesugen

Bioregulators Research compound (not approved for human use)

Synthetic tripeptide bioregulator (Lys-Glu-Asp) · also known as KED, Lys-Glu-Asp

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Vesugen (KED) is linked in the originating literature to vascular tissue and, more recently, to neuronal and Alzheimer's disease models. Its oral use in older adults with cognitive complaints has been reported by the same group, but vial-based regimens are community conventions.

Commonly reported dosing (20 mg vial)

Reconstituted with 3 mL → 6.667 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	500 mcg	0.075 mL	7.5
Standard	1.5 mg	0.225 mL	22.5
Higher	2 mg	0.3 mL	30

Frequency: Once daily, subcutaneous (8-12 week courses, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Reported in cell models to modulate genes for aging and apoptosis (p16, p21) and neuronal differentiation (nestin, GAP43); this mechanism is hypothesized.

Researched for

Studied in cell models of Alzheimer's disease for synaptic and gene-expression effects.
Examined in fibroblast and stem-cell aging cultures.
Described in reviews as a vasoprotective peptide in models of atherosclerosis and restenosis.

Notes

Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.